MedTrace Logo

Colchicine in Atrial Fibrillation to Prevent Stroke

NCT02282098 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-02-23

No results posted yet for this study

Summary

The purpose of this study is to determine the feasibility of performing a randomized controlled trial to investigate the efficacy of an anti-inflammatory drug, colchicine, at reducing well validated markers of thrombosis (D-dimer) and inflammation (hs-CRP).

Conditions

Interventions

DRUG

Colchicine

Colchicine 0.6mg twice daily

DRUG

Placebo

Placebo Colchicine

Sponsors & Collaborators

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Noel Chan, MD · Population Health Research Institute

  • John Eikelboom, MD · Population Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2020-11-17
Completion
2020-11-17

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02282098 on ClinicalTrials.gov